Drugs / Anti-CD19 iCAR NK Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03824951 | Feb 2019 → Jan 2020 | lymphoma | Allife Medical Science and Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD19 iCAR NK Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03824951 ↗ |
| Modality | Cell therapy | “Anti-CD19 iCAR NK Cells” NCT03824951 ↗ |
| Target | CD19 | “Anti-CD19 iCAR NK Cells” NCT03824951 ↗ |